Loading your page…
Loading your page…
Need dossiers on emerging incretins, mitochondrial peptides, or bespoke analogs? Query the Anubis registry and launch a detail page instantly.
Browse by modality
Shortcuts into the highest-signal clusters across peptides, incretins, neuropeptides, and mitochondrial programs.
55518 dossiers
FDA-approved therapeutic agents across diverse pharmacological categories.
184 dossiers
Antithyroid agents for hyperthyroidism and thyroid storm.
37 dossiers
Compounds classified in the Insulin family.
666 dossiers
Mineral supplements for potassium, magnesium, and electrolyte balance restoration.
1147 dossiers
Antimicrobial agents targeting bacterial infections across respiratory, systemic, and localized sites.
240 dossiers
Glucocorticoid anti-inflammatory agents for autoimmune, allergic, and inflammatory conditions.
28 dossiers
Mood-elevating agents modulating monoamine neurotransmitter systems.
698 dossiers
Essential micronutrients for metabolic function and deficiency prevention.
4 dossiers
Compounds classified in the Prodrug family.
104 dossiers
Azole and echinocandin antifungals for systemic and localized fungal infections.
124 dossiers
Local and general anesthetics for surgical procedures and pain management.
47 dossiers
Proton pump inhibitors reducing gastric acid for GERD and ulcer treatment.
147 dossiers
Non-steroidal anti-inflammatory drugs blocking cyclooxygenase for pain and inflammation control.
18 dossiers
Compounds classified in the Psychedelic family.
3 dossiers
Compounds classified in the Entactogen family.
182 dossiers
Endocrine modulators including estrogens, androgens, and pituitary hormones.
39 dossiers
H1 receptor antagonists for allergic rhinitis, urticaria, and motion sickness.
8 dossiers
Compounds classified in the Amino Acid family.
65 dossiers
Agents inhibiting viral replication for HIV, hepatitis, influenza, and herpes infections.
109 dossiers
Dopamine and serotonin receptor antagonists for schizophrenia and bipolar disorder management.
51 dossiers
Cytotoxic agents targeting rapidly dividing cells for cancer treatment.
94 dossiers
Small molecule tyrosine kinase blockers for targeted cancer therapy and inflammatory conditions.
12 dossiers
Compounds classified in the SARM family.
13 dossiers
Compounds classified in the Superfood family.
1 dossiers
Compounds classified in the Alcohol Treatment family.
201 dossiers
Nutritional supplements including minerals, amino acids, and metabolic cofactors.
3 dossiers
Cysteinyl leukotriene receptor blockers for asthma and allergies.
77 dossiers
Beta-2 agonists and anticholinergics for asthma and COPD airway management.
115 dossiers
Anti-epileptic compounds stabilizing neuronal membranes and modulating ion channels.
27 dossiers
Cognitive enhancers modulating acetylcholine, glutamate, and neurotrophic pathways.
16 dossiers
Osmotic and stimulant agents for constipation and bowel preparation.
119 dossiers
Engineered antibodies targeting specific antigens for cancer, autoimmune, and inflammatory diseases.
4 dossiers
Clot-dissolving agents for acute stroke, myocardial infarction, and pulmonary embolism intervention.
94 dossiers
CNS depressants binding opioid receptors for acute pain management and anesthesia protocols.
23 dossiers
L-type calcium channel antagonists for hypertension and angina control.
14 dossiers
Targeted therapies and immunomodulators engineered for precision cancer treatment and tumor suppression.
13 dossiers
Phosphodiesterase-5 blockers increasing cGMP for erectile dysfunction and pulmonary hypertension.
2 dossiers
Compounds classified in the ADHD Stimulant family.
26 dossiers
Compounds classified in the Anabolic Steroid family.
22 dossiers
Adrenergic receptor blockers for hypertension, arrhythmia, and heart failure.
17 dossiers
Incretin mimetics engineered for glycemic control, appetite suppression, and cardiometabolic optimization.
84 dossiers
Glucose-regulating compounds for type 1 and type 2 diabetes metabolic stabilization.
2 dossiers
Compounds classified in the Eugeroic family.
31 dossiers
CNS activators enhancing dopamine and norepinephrine for focus, alertness, and ADHD management.
26 dossiers
Calcineurin and mTOR inhibitors for transplant rejection and autoimmune diseases.
101 dossiers
Hormonal agents for pregnancy prevention and menstrual cycle regulation.
3 dossiers
Compounds classified in the Decongestant family.
18 dossiers
Blood thinning agents preventing clot formation for cardiovascular and thrombotic risk management.
9 dossiers
Platelet aggregation inhibitors for stroke and cardiovascular prevention.
100 dossiers
Renal agents promoting sodium and water excretion for hypertension and edema.
12 dossiers
Anti-nausea agents blocking 5-HT3 and dopamine receptors for chemotherapy-induced vomiting.
10 dossiers
Compounds classified in the Antioxidant family.
48 dossiers
GABA-A positive allosteric modulators for anxiety, seizure, and sleep disorders.
20 dossiers
Angiotensin-converting enzyme blockers for hypertension and heart failure management.
28 dossiers
HMG-CoA reductase inhibitors lowering LDL cholesterol for cardiovascular risk reduction.
14 dossiers
Insulin secretagogues stimulating pancreatic beta cells for diabetes.
6 dossiers
Sedative-hypnotics modulating GABA or melatonin pathways for insomnia treatment.
9 dossiers
Compounds classified in the Adaptogen family.
31 dossiers
Angiotensin II receptor blockers for hypertension and diabetic nephropathy protection.
10 dossiers
Orphan drug therapeutics addressing genetic and ultra-rare conditions with precision mechanisms.
37 dossiers
Mineralocorticoid receptor blockers for heart failure and hypertension.
31 dossiers
Peptide therapeutics accelerating tissue remodeling, neural recalibration, and metabolic control.
10 dossiers
Hematopoietic stimulators driving blood cell production and recovery protocols.
33 dossiers
Compounds classified in the Herbal family.
3 dossiers
Muscarinic receptor blockers for COPD, overactive bladder, and motion sickness.
19 dossiers
Eicosanoid analogs for glaucoma, labor induction, and gastroprotection.
5 dossiers
DHT blockers for benign prostatic hyperplasia and hair loss.
26 dossiers
Histamine-2 receptor antagonists reducing gastric acid secretion.
22 dossiers
Compounds classified in the Inhaled Steroid family.
35 dossiers
Skeletal muscle relaxants for acute musculoskeletal pain and spasm relief.
1 dossiers
Compounds classified in the Antiseptic family.
7 dossiers
GABA-A agonists for anesthesia, seizures, and insomnia (controlled substances).
12 dossiers
Sodium-glucose cotransporter blockers for diabetes and heart failure.
3 dossiers
Compounds classified in the Probiotic family.
4 dossiers
Anabolic agents promoting bone formation for osteoporosis.
2 dossiers
Compounds classified in the Opioid Treatment family.
3 dossiers
Compounds classified in the Anxiolytic family.
1 dossiers
Compounds classified in the Antipruritic family.
11 dossiers
Compounds classified in the Mineral family.
29 dossiers
Compounds classified in the Cannabinoid family.
2 dossiers
Compounds classified in the PPAR Agonist family.
3 dossiers
Compounds classified in the Protein family.
9 dossiers
Selective serotonin reuptake inhibitors for depression, anxiety, and mood disorder stabilization.
6 dossiers
Compounds classified in the Mushroom family.
2 dossiers
Compounds classified in the SSRI Antidepressant family.
1 dossiers
Compounds classified in the Beta-2 Agonist family.
1 dossiers
Compounds classified in the Fertility family.
1 dossiers
Compounds classified in the Stool Softener family.
5 dossiers
Compounds classified in the Racetam family.
1 dossiers
Compounds classified in the Topical Steroid family.
5 dossiers
Pancreatic enzyme replacements for exocrine insufficiency and malabsorption syndromes.
5 dossiers
Serotonin-norepinephrine reuptake inhibitors for depression, anxiety, and neuropathic pain.
11 dossiers
Dipeptidyl peptidase-4 blockers enhancing incretin hormones for diabetes.
2 dossiers
Compounds classified in the Cold Medicine family.
14 dossiers
Compounds classified in the Dissociative family.
2 dossiers
Osteoclast inhibitors for osteoporosis and bone metastases.
2 dossiers
Next-gen incretin analogs tuned for aggressive weight normalization and glycemic stability.
2 dossiers
Compounds classified in the SNRI Antidepressant family.
6 dossiers
Monoclonal antibodies and fusion proteins targeting autoimmune, inflammatory, and immunological disorders.
3 dossiers
Pain-relieving compounds acting on peripheral and central pain pathways.
5 dossiers
Bronchodilators and anti-inflammatory agents for asthma, COPD, and respiratory distress management.
3 dossiers
Compounds classified in the Depressant family.
1 dossiers
Compounds classified in the Antiflatulent family.
2 dossiers
Compounds classified in the Growth Hormone family.
2 dossiers
Compounds classified in the Growth Hormone Secretagogue family.
2 dossiers
Compounds classified in the Diabetes family.
2 dossiers
Ion channel correctors restoring chloride transport in cystic fibrosis pathology.
1 dossiers
Compounds classified in the Dissociative/Antidepressant family.
2 dossiers
Compounds classified in the Opioid-like family.
2 dossiers
Compounds classified in the Mood Stabilizer family.
2 dossiers
Compounds classified in the Fiber family.
3 dossiers
Agents for overactive bladder, urinary incontinence, and urinary retention.
3 dossiers
Compounds classified in the Antacid family.
2 dossiers
Naloxone and naltrexone reversing opioid effects and treating addiction.
6 dossiers
Rapid-acting insulin secretagogues for postprandial glucose control.
1 dossiers
Compounds classified in the Antidiarrheal family.
2 dossiers
PPAR-gamma agonists improving insulin sensitivity in type 2 diabetes.
1 dossiers
Compounds classified in the Hemorrhoid Treatment family.
1 dossiers
Compounds classified in the Triple Agonist family.
1 dossiers
Compounds classified in the Cough Suppressant family.
1 dossiers
Compounds classified in the Hair Loss family.
1 dossiers
Compounds classified in the GLP-1 Weight Loss family.
1 dossiers
Compounds classified in the ED Medication family.
2 dossiers
Compounds classified in the Rev-ErbA Agonist family.
1 dossiers
Synthetic levothyroxine and analogs for hypothyroidism replacement therapy.
1 dossiers
Compounds classified in the GLP-1/GIP Agonist family.
1 dossiers
Compounds classified in the Sleep/Antidepressant family.
1 dossiers
Small molecule kinase inhibitors modulating inflammatory and autoimmune signaling cascades.
3 dossiers
Compounds classified in the Thienodiazepine family.
9 dossiers
Compounds classified in the Designer Benzodiazepine family.
7 dossiers
Beta-keto amphetamine derivatives with stimulant and entactogenic effects.
10 dossiers
Compounds classified in the Plant family.
6 dossiers
Amphetamine-class compounds and derivatives acting on monoamine neurotransmitter systems.
6 dossiers
Compounds classified in the Amphetamine family.
4 dossiers
Dissociative anesthetics blocking NMDA receptors for analgesia and anesthesia.
7 dossiers
Indole alkaloids derived from tryptophan with serotonergic psychoactive properties.
1 dossiers
Compounds classified in the Phenmetrazine family.
1 dossiers
Nitrogen-containing organic compounds of plant origin with diverse pharmacological activities.
1 dossiers
Compounds classified in the Z-Drug family.
4 dossiers
Compounds classified in the Inhalant family.
2 dossiers
Compounds classified in the Acid family.
8 dossiers
Compounds classified in the Solvent family.
1 dossiers
Compounds classified in the Salt family.
1 dossiers
Compounds classified in the Base family.
2 dossiers
Compounds classified in the Reagent family.
1 dossiers
Compounds classified in the Catalyst family.
2 dossiers
Compounds classified in the Oxidizer family.
7 dossiers
Compounds classified in the Precursor family.
4 dossiers
Compounds classified in the Excipient family.
5 dossiers
Compounds classified in the Gas family.
1 dossiers
Neuromodulatory signals engineered for cognitive resilience and appetite governance.
Tiered classification
Fast pivots for safety clearance teams and institutional review boards.